Ann: Appendix 3B - Release of securities from escrow, page-5

The other words that rang loud and clear in the presentation and seemed to be highlighted larger than others were:
"• PTX’s AML program was a clear focus of interest from both clinicians and specialist biotech funds in the US this year"It seems to me that specialist biotech funds could have already had a word in the ear of our good professor Sebti or vice versa
look at the facts and how the ducks line up...Professor Sebti is the inventor of the PTX100and PTX200 molecule,he is the head of drug discovery at the prestigous H.Lee Moffit cancer research institute,Professor Lancet was an investigator on PTX’s earlier Phase 1 AML clinical trial conducted at MD Anderson and Moffitt Cancer Center in 32 patients with advanced haematologic malignancies,Professor Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematological malignancies, with a particular focus on leukaemias.
The brightest minds in the world are working to solve acute myeloma average time span to death of 5 years.Success as a commensense pointer I would think would be to extend the years of survival past 5 and that would be enough to interest the medical industry, so a partial success will be an enormous success to PTX.

Anyway I am looking forward to what next year brings,this is a nice thread with nice people and I hope it keeps that way.I wish you all a very merry Christmas and a happy new year